Viewing Study NCT06614322



Ignite Creation Date: 2024-10-26 @ 3:41 PM
Last Modification Date: 2024-10-26 @ 3:41 PM
Study NCT ID: NCT06614322
Status: NOT_YET_RECRUITING
Last Update Posted: None
First Post: 2024-09-23

Brief Title: SPENDD Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy
Sponsor: None
Organization: None

Study Overview

Official Title: Sensory Phenotyping to Enhance Neuropathic Pain Drug Development SPENDD a Randomized Double-blinded Cross-over Clinical Trial Aimed At Investigating Whether Bedside Quantitative Sensory Testing Can Predict Response to Analgesics
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The goal of this clinical trial is to determine whether quantitative sensory testing QST can be used to classify participants into pain sub-groups and predict who will respond best to certain pain treatments in participants with painful peripheral neuropathy

The analgesic effect is evaluated by measuring pain intensity and Patient Global Impression of Change PGIC

This study is a 3-period cross-over trial This means researchers will compare 3 different drugs pregabalin duloxetine and placebo over a period of 19 weeks

Participants will

Undergo a quantitative sensory testing QST exam
Provide a blood sample
Complete questionnaires on the computer
Take the study drug as instructed
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None